Ambu A/S (OTCMKTS:AMBBY) Stock Price Down 12.7% - Here's Why

Key Points

• Ambu A/S stock price dropped by 12.7% to $13.73 amid increased trading volume.
• UBS Group upgraded Ambu A/S to a "strong-buy" rating on May 13th, indicating a bullish outlook on the stock's performance.
• The company has a market capitalization of $3.23 billion with a PE ratio of 72.27 and reported earnings of $0.10 per share for the last quarter.

Ambu A/S Unsponsored ADR (OTCMKTS:AMBBY - Get Free Report) shares fell 12.7% during mid-day trading on Thursday . The company traded as low as $13.73 and last traded at $13.73. 406 shares were traded during mid-day trading, an increase of 157% from the average session volume of 158 shares. The stock had previously closed at $15.74.

Wall Street Analysts Forecast Growth

Separately, UBS Group raised Ambu A/S to a "strong-buy" rating in a research report on Tuesday, May 13th.

Ambu A/S Stock Performance

The stock has a market capitalization of $3.23 billion, a PE ratio of 72.27 and a beta of 0.89. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.67 and a current ratio of 2.88. The firm has a 50 day moving average of $15.20 and a 200-day moving average of $16.69.

Ambu A/S (OTCMKTS:AMBBY - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share for the quarter. Ambu A/S had a return on equity of 6.31% and a net margin of 6.21%.

About Ambu A/S

Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, cystoscopes, and display units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.